Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Histopathology. 2019 Sep 9;76(2):191–200. doi: 10.1111/his.13946

Table 1.

PD-L1 antibody clones and recommended algorithms to -identify PD-L1 immunopositivity determined in clinical trial settings.

PD-L1 antibody Clones UC HSCC BC
22C3 CPS ≥ 10 CPS ≥ 1 CPS ≥ 1
SP142 IC ≥ 5% IC ≥ 5% IC ≥ 1%
SP263 TC ≥ 25% or IC ≥ 25% TC ≥ 25% NA

UC: urothelial carcinoma, HSCC: head and neck squamous cell carcinoma, BC: breast carcinoma, NA: not available.